PMGC HOLDINGS INC. Cost of Revenue
PMGC HOLDINGS INC. (ELAB) reported Cost of Revenue of $920.92 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-14
- PMGC HOLDINGS INC. cost of goods and services sold for the quarter ending 2026-06-30 was $920.92K.
- PMGC HOLDINGS INC. cost of goods and services sold for the quarter ending 2026-03-31 was $451.52K.
- PMGC HOLDINGS INC. cost of goods and services sold for the quarter ending 2025-12-31 was $196.85K.
- PMGC HOLDINGS INC. cost of goods and services sold for the quarter ending 2025-09-30 was $207.92K.
- PMGC HOLDINGS INC. cost of goods and services sold for fiscal 2025 was $404.77K.
- PMGC HOLDINGS INC. cost of goods and services sold for fiscal 2023 was $578.01K, a 81.21% increase from fiscal 2022.
- PMGC HOLDINGS INC. cost of goods and services sold for fiscal 2022 was $318.97K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $920.92K 10-Q · filed 2026-08-14 | $1.37M 10-Q · filed 2026-08-14 | $1.57M derived: sum of 3 quarters · filed 2026-08-14 | $1.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $451.52K 10-Q · filed 2026-05-15 | $648.37K derived: sum of 2 quarters · filed 2026-05-15 | $856.29K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2025-12-31 | $196.85K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $404.77K derived: sum of 2 quarters · filed 2026-03-30 | $404.77K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $207.92K 10-Q · filed 2025-11-14 | $207.92K 10-Q · filed 2025-11-14 | ||
| 2024-03-31 | $168.91K 10-Q · filed 2024-05-15 | -$340.38M derived: sum of 2 quarters · filed 2024-05-15 | -$151.87M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2023-12-31 | -$340.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$152.03M derived: sum of 2 quarters · filed 2024-03-29 | $578.01K 10-K · filed 2024-03-29 | |
| 2023-09-30 | $188.51M 10-Q · filed 2023-12-11 | $341.12M 10-Q · filed 2023-12-11 | ||
| 2023-03-31 | $44.43K 10-Q · filed 2024-05-15 | -$273.12M derived: sum of 2 quarters · filed 2024-05-15 | -$78.69M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$273.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$78.73M derived: sum of 2 quarters · filed 2024-03-29 | $318.97K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $194.43M 10-Q · filed 2023-12-11 | $273.48M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |